Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
NCT ID | NCT04530565 |
Title | Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults |
Recruitment | Recruiting |
Gender | both |
Phase | Phase III |
Variant Requirements | No |
Sponsors | National Cancer Institute (NCI) |
Indications | |
Therapies |
Cyclophosphamide + Dasatinib + Dexamethasone + Doxorubicin + Vincristine Sulfate Blinatumomab + Dexamethasone + Ponatinib + Prednisone Blinatumomab + Dasatinib + Dexamethasone + Prednisone Blinatumomab + Dexamethasone + Methotrexate + Ponatinib + Prednisone Blinatumomab + Dasatinib + Dexamethasone + Methotrexate + Prednisone Cytarabine + Methotrexate + Ponatinib Cytarabine + Dasatinib + Methotrexate Cyclophosphamide + Dexamethasone + Doxorubicin + Ponatinib + Vincristine Sulfate |
Age Groups: | senior | adult |
Covered Countries | USA |